Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gastroenterology Endpoints For IBD Drugs Once Again In FDA Spotlight

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is holding another workshop to discuss selection of endpoints in development of drugs to treat pediatric and adult inflammatory bowel diseases; the agency held four gastroenterology workshops last year.

You may also be interested in...



Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD

Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.

FDA, Industry Seek Temporary Endpoint For Assessing Ulcerative Colitis Drugs

Panelists at an agency workshop discussed tweaks to the Mayo Clinic Score while patient-reported outcome instruments are being developed in an initiative to create an improved ulcerative colitis endpoint.

Pediatric IBD Studies Should Assess Disease Activity, Panel Says

Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel